Clinical trial
Anthrax-rPA: Safety, Tolerability, Immunogenicity
NCT00063843 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00063843 |
|---|---|
| Title | Anthrax-rPA: Safety, Tolerability, Immunogenicity |
| Official title | A Phase I, Dose-Escalating Study to Assess the Safety, Tolerability, and Immunogenicity of Recombinant Anthrax Protective Antigen Vaccine (rPA) Administered in Two Intramuscular Doses to Healthy Adults |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Anthrax |
| Intervention type | Biological |
| Interventions | Recombinant Protective Antigen, Anthrax Vaccine Adsorbed |
| Enrollment | 80 |
| Start date | Jul 1, 2003 |
| Completion | Aug 1, 2005 |
| First posted | Jul 8, 2003 |
| Last update posted | Aug 27, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: